Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Truist Securities analyst Joon Lee maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and lowers the price target from $...
Cantor Fitzgerald analyst Eric Schmidt reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral.
The "Mad Money" host says Dexcom had "a real bad miss... they still really haven't fully explained why that is....
Barclays analyst Gena Wang maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Equal-Weight and lowers the price target from ...
RBC Capital analyst Luca Issi maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Sector Perform and lowers the price target ...
Stifel analyst Benjamin Burnett maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Hold and lowers the price target from $60...
Chardan Capital analyst Geulah Livshits maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and lowers the price target f...
Needham analyst Gil Blum maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and lowers the price target from $88 to $84.
CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(1.49) per share which beat the analyst consensus estimate of $...
